Evaluation of appropriate use and clinical outcomes of idarucizumab as antidote of dabigatran in daily clinical practice

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Mr Sake van der Wall

Onze Lieve Vrouwe Gasthuis, Haarlem (Netherlands (The))

10 More presentations in this session

Presentation thumbnail

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study

Doctor X. Li (Princeton, US)

Abstract Slides

Presentation thumbnail

Age threshold for ischemic stroke risk in atrial fibrillation: cohort data covering the entire Korean population

Associate Professor H. Yu (Seoul, KR)

Presentation thumbnail

Antiplatelet therapy use in atrial fibrillation patients taking oral anticoagulation: an analysis of adverse outcomes from the FANTASIIA registry.

Doctor M. Esteve Pastor (Murcia, ES)

Presentation thumbnail

The new warfarin dosing algorithm for patients with atrial fibrillation and severe chronic kidney disease

Doctor Z. Salpagarova (Moscow, RU)

Presentation thumbnail

Serum light-chain neurofilament, a brain lesion marker, correlates with CHA2DS2-VASc score among patients with atrial fibrillation: a cross-sectional study

Doctor S. Aeschbacher (Basel, CH)

Access the full session

Session thumbnail

Poster Session 3 - Atrial fibrillation - Stroke prevention

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

State-of-the-art lecture on stroke prevention in atrial fibrillation

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources